Skip to main content
OpenTrials

Clinical trial condition

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Explore clinical trials studying Paroxysmal Nocturnal Hemoglobinuria (PNH). Study availability and eligibility vary by location and protocol.

33 public trials 9 recruiting studies
Refine in advanced search Browse all conditions

Paroxysmal Nocturnal Hemoglobinuria (PNH) trial results

Completed

Study of Efficacy and Safety of Twice Daily Oral Iptacopan (LNP023) in Adult PNH Patients Who Are Naive to Complement Inhibitor Therapy

NCT04820530

Conditions
Anemia, Anemia, Hemolytic, Bone Marrow Diseases, +5 more
Locations
  • Novartis Investigative Site Beijing, China
  • Novartis Investigative Site Tianjin, China
  • Novartis Investigative Site Tianjin, China
  • Novartis Investigative Site Paris, France
View Trial Details
Completed

Study of Efficacy and Safety of Twice Daily Oral LNP023 in Adult PNH Patients With Residual Anemia Despite Anti-C5 Antibody Treatment

NCT04558918

Conditions
Anemia, Anemia, Hemolytic, Bone Marrow Diseases, +5 more
Locations
  • City Of Hope National Med Center City of Hope Medical Center Duarte, California, United States
  • Univ Cali Irvine ALS Neuromuscular Orange, California, United States
  • Augusta University Georgia Patient Treatment Augusta, Georgia, United States
  • Levine Cancer Insitute Carolinas Healthcare System Charlotte, North Carolina, United States
View all 39 locations
View Trial Details
Completed

ALXN1210 (Ravulizumab) Versus Eculizumab in Complement Inhibitor Treatment-Naïve Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)

NCT02946463

Conditions
Anemia, Anemia, Hemolytic, Bone Marrow Diseases, +5 more
Locations
  • Research Site Los Angeles, California, United States
  • Research Site Whittier, California, United States
  • Research Site Fort Worth, Texas, United States
  • Research Site Buenos Aires, Argentina
View all 120 locations
View Trial Details
Completed

Phase 2 Safety and Efficacy Study of Zilucoplan (RA101495) to Treat PNH Patients Who Have an Inadequate Response to Eculizumab

NCT03030183

Conditions
Anemia, Anemia, Hemolytic, Bone Marrow Diseases, +5 more
Locations
  • Investigative Site Duarte, California, United States
  • Investigative Site Los Angeles, California, United States
  • Investigative Site Chicago, Illinois, United States
  • Investigative Site Manhasset, New York, United States
View Trial Details
Completed

A Phase I Study to Assess the Safety of Pegcetacoplan (APL-2) as an Add-On to Standard of Care in Subjects With PNH

NCT02264639

Conditions
Anemia, Anemia, Hemolytic, Bone Marrow Diseases, +18 more
Locations
  • University of Southern California Norris Comprehensive Cancer Center Los Angeles, California, United States
  • Lakes Research Miami Lakes, Florida, United States
  • University of Lousiville Louisville, Kentucky, United States
  • John Hopkins Hospital Baltimore, Maryland, United States
View Trial Details

Related conditions